The abstract is read at the publisher; the summary is JClub's.
Higher preoperative circulating eosinophil counts are linked to significantly improved recurrence-free and distant metastasis-free survival in hormone receptor-positive/HER2-negative breast cancer, validated in 23,170 patients.
- Why it matters: This subtype lacks simple, noninvasive biomarkers to estimate recurrence risk and identify who benefits from adjuvant CDK4/6 inhibition.
- What they did: The study tested eosinophil counts in a discovery cohort (N = 472) and validated associations in an expanded cohort (N = 23,170) using propensity score overlap weighting, then assessed additive value beyond 21-gene recurrence scores (n = 2,973) and prediction for CDK4/6 inhibitors in high-risk patients (n = 3,471). Mechanisms used integrated multiomics, spatial digital pathology, and in vivo mouse models with eosinophil adoptive transfer.
- The result: Elevated eosinophils were associated with lower human leukocyte antigen homozygosity and increased intratumoral immune activation, with CD8+ T-cell involvement; adoptive transfer reduced tumor burden in EMT6 (BALB/c) and E0771 (C57BL/6). Eosinophil levels added prognostic value beyond the 21-gene RS and predicted the CDK4/6 inhibitor–benefiting subset among high-risk patients.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.